Lisata Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: LSTA · Form: 8-K · Filed: Jun 10, 2025 · CIK: 320017

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, filing-update

Related Tickers: LISATA

TL;DR

Lisata Therapeutics (LISATA) is having a shareholder vote on corporate matters.

AI Summary

Lisata Therapeutics, Inc. filed an 8-K on June 10, 2025, to report on the submission of matters to a vote of security holders. The company, formerly known as Caladrius Biosciences, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates that Lisata Therapeutics is seeking shareholder approval for certain corporate actions, which could impact the company's future strategic direction and governance.

Risk Assessment

Risk Level: low — The filing is procedural, reporting on a shareholder vote, and does not disclose new financial or operational risks.

Key Players & Entities

FAQ

What specific matters are being submitted for a vote by Lisata Therapeutics' security holders?

The filing states that the report concerns 'Submission of Matters to a Vote of Security Holders,' but the specific details of these matters are not provided in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on June 10, 2025, which is also the date of the report.

What was Lisata Therapeutics, Inc. formerly known as?

Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc.

In which state is Lisata Therapeutics, Inc. incorporated?

Lisata Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Lisata Therapeutics, Inc.?

The principal executive office address for Lisata Therapeutics, Inc. is 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding LISATA THERAPEUTICS, INC. (LSTA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing